#obesity treatment
Total 3 articles
EconomyEN
Novo Nordisk's Obesity Drug Stumble: What It Means for Your Wallet
Novo Nordisk's CagriSema disappoints in trials against Eli Lilly's obesity treatments. Analysis of the trillion-dollar market battle and implications for patients and investors.
EconomyEN
Lilly Bets $1.5B on Weight-Loss Pills Before FDA Says Yes
Eli Lilly stockpiles $1.5 billion of oral Zepbound ahead of FDA approval, signaling confidence in weight-loss pill market disruption
EconomyEN
No More Yo-Yo: Japan's New Obesity Drug Targets Rebound Weight Gain
Chugai Pharmaceutical and Roche develop next-generation obesity treatment designed to prevent weight regain after stopping medication. Approval targeted for 2028 in competitive market.
PRISM by Liabooks
PRISM
Advertise with Us
Place your ad in this space
[email protected]